140 related articles for article (PubMed ID: 2233757)
1. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
[TBL] [Abstract][Full Text] [Related]
2. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
Vogel CW; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
[TBL] [Abstract][Full Text] [Related]
5. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME
J Clin Invest; 1988 Apr; 81(4):1122-8. PubMed ID: 2450893
[TBL] [Abstract][Full Text] [Related]
6. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
[TBL] [Abstract][Full Text] [Related]
7. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
Müller B; Müller-Ruchholtz W
Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
[TBL] [Abstract][Full Text] [Related]
8. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
9. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
10. Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization.
Petrella EC; Wilkie SD; Smith CA; Morgan AC; Vogel CW
J Immunol Methods; 1987 Nov; 104(1-2):159-72. PubMed ID: 3500233
[TBL] [Abstract][Full Text] [Related]
11. Selective antitumor effect of thioether-linked immunotoxins composed of gelonin and monoclonal antibody to alpha-fetoprotein or its F(ab')2 fragment.
Masuda K; Takahashi K; Hirano K; Takagishi Y
Tumour Biol; 1994; 15(3):175-83. PubMed ID: 7521059
[TBL] [Abstract][Full Text] [Related]
12. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
13. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
14. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
15. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
16. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
Kushner BH; Cheung NK
Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
[TBL] [Abstract][Full Text] [Related]
17. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Raso V; Ritz J; Basala M; Schlossman SF
Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate-directed conjugation of cobra venom factor to antibody by selective derivatization of the terminal galactose residues.
Fu Q; Gowda DC
Bioconjug Chem; 2001; 12(2):271-9. PubMed ID: 11312689
[TBL] [Abstract][Full Text] [Related]
20. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
